Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned an average recommendation of “Buy” from the twenty-three research firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, sixteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $146.18.

ALNY has been the subject of several recent research reports. BidaskClub lowered Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 12th. ValuEngine lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 21st. Piper Jaffray Companies lowered their target price on Alnylam Pharmaceuticals from $182.00 to $160.00 and set an “overweight” rating for the company in a report on Wednesday, June 27th. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 4th. Finally, Cowen reiterated a “buy” rating and set a $157.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 2nd.

Shares of NASDAQ:ALNY traded down $3.10 during trading on Wednesday, hitting $94.04. 14,544 shares of the company traded hands, compared to its average volume of 999,319. The firm has a market capitalization of $9.54 billion, a PE ratio of -17.99 and a beta of 2.58. Alnylam Pharmaceuticals has a one year low of $74.50 and a one year high of $153.99. The company has a current ratio of 13.22, a quick ratio of 13.22 and a debt-to-equity ratio of 0.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.11. The company had revenue of $29.91 million during the quarter, compared to analyst estimates of $16.96 million. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The business’s revenue was up 87.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.07) earnings per share. analysts predict that Alnylam Pharmaceuticals will post -7.27 EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 1,563 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The stock was sold at an average price of $105.04, for a total value of $164,177.52. Following the completion of the sale, the senior vice president now directly owns 16,063 shares in the company, valued at $1,687,257.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Maraganore sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 25th. The stock was sold at an average price of $105.39, for a total value of $5,269,500.00. Following the completion of the sale, the chief executive officer now owns 201,297 shares of the company’s stock, valued at $21,214,690.83. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,063 shares of company stock valued at $5,733,678. Insiders own 4.30% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB lifted its position in Alnylam Pharmaceuticals by 3.1% in the second quarter. Xact Kapitalforvaltning AB now owns 15,929 shares of the biopharmaceutical company’s stock worth $1,569,000 after purchasing an additional 486 shares during the period. Guggenheim Capital LLC lifted its position in Alnylam Pharmaceuticals by 1.1% in the first quarter. Guggenheim Capital LLC now owns 53,084 shares of the biopharmaceutical company’s stock worth $6,323,000 after purchasing an additional 600 shares during the period. BTG Pactual Global Asset Management Ltd lifted its position in Alnylam Pharmaceuticals by 17.3% in the second quarter. BTG Pactual Global Asset Management Ltd now owns 4,410 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 652 shares during the period. Toronto Dominion Bank lifted its position in Alnylam Pharmaceuticals by 16.1% in the first quarter. Toronto Dominion Bank now owns 6,058 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 842 shares during the period. Finally, American International Group Inc. lifted its position in Alnylam Pharmaceuticals by 44.8% in the first quarter. American International Group Inc. now owns 2,906 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 899 shares during the period. Hedge funds and other institutional investors own 93.36% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Recommended Story: Analyst Ratings

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.